The present invention relates to small lipid nanoparticles, a small lipid nanoparticle (SLNP)-based nanovaccine platform including same, and a combination treatment regimen with an immune checkpoint inhibitor. Lipid nanoparticies according to the present invention can easily deliver antigens and anionic drugs into cells, and exhibit strong anti-tumor effects when loaded with tumor-associated antigens. Particularly, a cancer vaccine kit according to the present invention including lipid nanoparticles according to the present invention as a first vaccine composition and lipid nanoparticles and an immune checkpoint inhibitor as a second vaccine composition can be used to effectively suppress tumor regrowth and recurrence triggered by the occurrence of immunosuppression against a cancer nanovaccine.

The present invention provides a vaccine for preventing and/or treating infections with human papillomavirus. The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the E6 and E7 antigens of human papillomavirus, wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein R.sup.1 and R.sup.2 each independently represent a C.sub.1-C.sub.3 alkyl group;
L.sup.1 represents a C.sub.17-C.sub.19 alkenyl group which may have one or a plurality of C.sub.2-C.sub.4 alkanoyloxy groups;
L.sup.2 represents a C.sub.10-C.sub.19 alkyl group which may have one or a plurality of C.sub.2-C.sub.4 alkanoyloxy groups or a C.sub.10-C.sub.19 alkenyl group which may have one or a plurality of C.sub.2-C.sub.4 alkanoyloxy groups; and
p is 3 or 4.

The present invention relates to a T cell receptor (TCR) capable of binding to a PRAME peptide having the amino acid sequence SLLQHLIGL (SEQ ID NO: 1) or a portion thereof, or its HLA-A2 bound form. Also encompassed in the present invention is a nucleic acid encoding a TCR, a vector comprising the nucleic acid, and a host cell comprising the TCR, the nucleic acid sequence, or said vector. Comprised is further, a method for obtaining a TCR described herein, a pharmaceutical or diagnostic composition, and a method of detecting the presence of a cancer in a subject in vitro. Furthermore, the present invention relates to the use of a TCR, a nucleic acid and/or a vector for generating modified lymphocytes

The present disclosure provides a composition for preventing an immune disorder, recovering from an immune disorder, preventing an immune disorder from occurring and preventing or treating a disease, disorder or condition. The present disclosure provides a composition for preventing an immune disorder, recovering from an immune disorder, preventing an immune disorder from occurring and preventing or treating a disease, disorder or condition in a subject, said composition comprising an antigen component, which is specific to the subject (or immunological memory of which remains in the subject), against a component which is different from a causative factor of the disease, disorder or condition.

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of the cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

The present invention relates to RNA, particularly an immunostimulatory RNA (isRNA), a coding RNA or a combination thereof, for use in the treatment or prophylaxis of a disease, in particular a tumor and/or cancer disease. The present invention also provides pharmaceutical compositions, and a kit comprising the RNA(s). Further, the invention also comprises medical uses of the RNA(s) and compositions comprising the RNA(s).

An engineered Newcastle Disease Virus (NDV) vector is provided. In particular, the present disclosure provides methods of treating or preventing a disease such as cancer, or an infectious disease, or methods for eliciting an immune response, with the engineered NDV vector. The engineered NDV vector provided herein is useful as an immunogenic composition, an oncolytic agent, or a vaccine.

Provided herein are methods and compositions related to EVs useful as therapeutic agents.

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Merkel Cell Polyomavirus (MCV) T antigen. Immunomodulatory methods and methods of inducing an immune response against MCV are disclosed. Method of treating infection by MCV and methods of treating or preventing Merkel Cell Carcinoma associated with MCV are disclosed. Modified consensus MCV T antigens are disclosed.